» Articles » PMID: 28371641

Recent Progress in the Identification of Selective Butyrylcholinesterase Inhibitors for Alzheimer's Disease

Overview
Journal Eur J Med Chem
Specialty Chemistry
Date 2017 Apr 4
PMID 28371641
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is one of the most prevalent neurodegenerative disorders with notable factor of dysfunction in cholinergic system. Low ACh level can be observed in the pathogenesis of AD. Several AChE inhibitors have already been used for clinical treatments. However, other than normal conditions, ACh is mostly hydrolyzed by BuChE in progressed AD. Account for an increased level of BuChE and decreased level of AChE in the late stage of AD, development of selective BuChE inhibitor is of vital importance. Up till now, compounds with various scaffolds have been discovered to selectively inhibit BuChE. Different effective anti-BuChE molecules are concluded in this review.

Citing Articles

In silico molecular docking and molecular dynamic simulation of agarwood compounds with molecular targets of Alzheimer's disease .

Alugoju P, Vishnu Bhandare V, Patil V, V K D K, Borugadda P, Tencomnao T F1000Res. 2025; 12:230.

PMID: 39931160 PMC: 11809694. DOI: 10.12688/f1000research.130618.2.


Advances in Cholinesterase Inhibitor Research-An Overview of Preclinical Studies of Selected Organoruthenium(II) Complexes.

Zuzek M Int J Mol Sci. 2024; 25(16).

PMID: 39201735 PMC: 11354293. DOI: 10.3390/ijms25169049.


Design, synthesis and biological evaluation of 1-aryldonepezil analogues as anti-Alzheimer's disease agents.

Luo J, Xu J, Ren H, Xu J, Gao F, Fang D Future Med Chem. 2024; 16(10):983-997.

PMID: 38910574 PMC: 11221548. DOI: 10.4155/fmc-2023-0369.


The Cholinergic Selectivity of FDA-Approved and Metabolite Compounds Examined with Molecular-Docking-Based Virtual Screening.

Gambardella M, Wang Y, Pang J Molecules. 2024; 29(10).

PMID: 38792196 PMC: 11124253. DOI: 10.3390/molecules29102333.


Development of novel 9H-carbazole-4H-chromene hybrids as dual cholinesterase inhibitors for the treatment of Alzheimer's disease.

Sharon N, Ugale V, Padmaja P, Lokwani D, Salunkhe C, Shete P Mol Divers. 2024; 29(1):379-396.

PMID: 38683486 DOI: 10.1007/s11030-024-10859-z.